Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as [14C]-GDC-0980
GDC-0980 · 7 trials · 5 indications
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| Everolimus | ACTIVE_COMPARATOR | Participants will receive everolimus (10 mg) orally daily until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination. |
| GDC-0980 | EXPERIMENTAL | Participants will receive GDC-0980 (40 mg) orally daily until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination. |
| B | EXPERIMENTAL | - |
| C | EXPERIMENTAL | - |
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| GDC-0980 | DRUG | Oral daily dose |
| Everolimus | DRUG | Everolimus will be administered orally at a 10 mg daily dose. |
| bevacizumab | DRUG | Intravenous repeating dose |
| carboplatin | DRUG | Intravenous repeating dose |
| cisplatin | DRUG | intravenous repeating dose |
| paclitaxel | DRUG | Intravenous repeating dose |
| pemetrexed | DRUG | intravenous repeating dose |
| capecitabine | DRUG | Oral repeating dose |
| mFOLFOX6 | DRUG | Intravenous repeating dose |
Inclusion Criteria: * Patients must have recurrent or persistent endometrial carcinoma that is refractory to curative therapy or established treatments * Histologic confirmation of the original primary tumor is required * Histologic or cytologic confirmation of the recurrent/progressive disease is ...
GDC-0980 is an investigational small molecule developed by Roche Holding AG for oncology. It has been studied in breast cancer, endometrial carcinoma, non-Hodgkin's lymphoma, renal cell carcinoma, and other solid cancers. It is not approved and remains in clinical development.
GDC-0980 was studied in a Phase 2 trial for recurrent or persistent endometrial carcinoma. That trial, NCT01455493, enrolled 56 female participants aged 18 and older in the United States and has completed. GDC-0980 is investigational and has not been approved for this or any indication.
GDC-0980 is developed by Roche Holding AG, which trades over the counter under the ticker RHHBY. Roche sponsored the clinical program evaluating the compound across several tumor types, including endometrial carcinoma, renal cell carcinoma, and advanced solid tumors.
GDC-0980 has been evaluated in Phase 1 and Phase 2 clinical trials, all of which are completed. No trials are currently active. The compound is investigational and has not received FDA approval for any indication.
GDC-0980 has been studied in completed trials including NCT01455493 in endometrial carcinoma, NCT01442090 comparing it with everolimus in metastatic renal cell carcinoma, NCT01332604 in advanced solid tumors, and NCT01301716 in solid tumors. These trials enrolled a combined total of 257 participants.
Yes, [14C]-GDC-0980 is an alternative name for GDC-0980. The bracketed label refers to the carbon-14 radiolabeled form used in study work. Both names refer to the same Roche investigational small molecule being evaluated in oncology.